US Stocks
Replimune Group Inc
Replimune Group Inc

Replimune Group Inc (REPL)


  • $







Key Stats

Today Low/High$28.86 / $29.22
52 Week Low/High$27.66 / $54.85
Market Cap$1.34B

Company Details

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune's Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications.
OrganisationReplimune Group Inc
HeadquatersWoburn, Massachusetts, United States
IndustryHealth Technology
CEORobert Coffin

Discover more

Frequently Asked Questions

What is Replimune Group Inc (REPL) share price today?

Can Indians buy Replimune Group Inc (REPL) shares?

How can I buy Replimune Group Inc (REPL) shares from India?

Can Fractional shares of Replimune Group Inc (REPL) be purchased?

What are the documents required to start investing in Replimune Group Inc (REPL) stocks?

We are a SEBI registered investement advisor